Brief: Mesoblast To Meet With FDA Next Month To Discuss Rexlemestrocel-L And Opioid Cessation
05/11/2025 01:34
Nov 5 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST TO MEET WITH FDA NEXT MONTH TO DISCUSS REXLEMESTROCEL-L AND OPIOID CESSATION Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M